Quarterly ResultMay 7, 2026, 04:12 PM
Reliance Global Group Expands Investments, Q1 Net Loss Improves to $1.4M
AI Summary
Reliance Global Group, Inc. reported Q1 2026 financial results, showing an improved net loss of $1.4 million compared to $1.7 million in the prior year. The company advanced its Scale51 strategy by increasing its ownership in Enquantum to approximately 29% and launching LifeSci Global Group with an initial investment in Innervate Radiopharmaceuticals. While commission income decreased due to 2025 portfolio realignment, the company strengthened its balance sheet with increased cash and working capital, and improved net income in its Insurance Segment.
Key Highlights
- Increased ownership in Enquantum to approximately 29% through additional milestone-based funding.
- Launched LifeSci Global Group and made a strategic investment in Innervate Radiopharmaceuticals.
- Net loss improved to approximately $1.4 million for Q1 2026, compared to $1.7 million in prior year.
- Unrestricted cash increased by 73% to approximately $2.3 million as of March 31, 2026.
- Working capital increased by 39% to approximately $2.6 million as of March 31, 2026.
- Stockholders’ equity increased by 16% to approximately $7.4 million.
- Commission income was approximately $3.8 million, down from $4.2 million in Q1 2025.
- Insurance Segment net income improved to approximately $0.7 million from $0.5 million in Q1 2025.